To The Moon

$Novo-Nordisk A/S(NVO)$

Market Performance: Worst Week in 2025 So Far

Last week, we saw the worst performance in the S&P 500 so far in 2025. However, one of the best-performing industries was healthcare—excluding Eli Lilly, which dropped 8%.

Year-to-Date Trends: Healthcare Stands Strong

Looking at the year-to-date performance, the market has been largely in the red, but healthcare remains one of the strongest sectors. Even Eli Lilly, despite its recent decline, is still up around 11% for the year.

Market Outlook: Wall Street Predicts Further Declines

As we head into today's market, Wall Street is warning of further declines in global stocks, with pre-market indicators looking weak. The Dow is down nearly 500 points, driven by an intense market selloff fueled by growing recession fears. The Fear & Greed Index, which was at 20 at the previous close, has now dropped to 17.

Focus on Novo Nordisk: A Stock Under Pressure

Today, our focus is on Novo Nordisk, which is down approximately 9%. We'll explore why the company is declining and whether its current 52-week low presents a strong buying opportunity. Both Wall Street and Seeking Alpha consider Novo Nordisk a "buy," despite its 39% drop over the past year. However, over the last decade, the stock has significantly outperformed the S&P 500, rising 235%.

The Cause of Novo Nordisk’s Decline: Trial Results Disappoint

So, what’s behind Novo Nordisk’s decline? While the stock was down only 6.3% in pre-market trading, the losses have deepened. The company recently released trial results for its next-generation weight-loss drug, KriSema. The data shows that obese or overweight adults with type 2 diabetes lost about 15.7% of their weight after 68 weeks (a little over a year). This is well below the initial forecast of 25% and lower than the 22.7% seen in a December trial. The market had high hopes for KriSema as the next breakthrough in weight-loss treatment, given Novo Nordisk’s success with Wegovy and Ozempic.

Institutional Investor Confidence: Mixed Signals

Institutional investors currently hold about 112% ownership of the company. Over the past year, they sold around $4 billion worth of shares but also increased their positions by roughly 50% in the same period—indicating strong institutional confidence in Novo Nordisk.

Valuation: Undervalued or Justified Premium?

From a valuation standpoint, the stock appears significantly undervalued. The forward P/E ratio sits at 20.3, well below its five-year average of 30.4. The dividend yield theory also signals undervaluation, with the current yield at 2.01%, compared to a five-year average of 1.41%. Additionally, the expected fair price trend shows a widening gap between where the stock currently trades and even the lower end of its fair value estimate.

A Discount Worth Considering?

Although Novo Nordisk’s valuation grade is a D-minus—partially due to the sector’s lower average P/E of 18—the stock still trades at a discount relative to its own historical levels. While it does carry a 22% premium compared to the sector, its long-term performance and historical valuation suggest that the premium may be justified.

Novo Nordisk: A Global Pharmaceutical Leader

Novo Nordisk is now one of the largest pharmaceutical companies in the world, second only to Eli Lilly, with Johnson & Johnson trailing behind.

Strong Earnings Growth and Revenue Breakdown

In their most recent earnings report, Novo Nordisk posted a 30% year-over-year revenue increase. Their GLP-1 drug segment remains the largest contributor, growing by 12%, while their obesity treatment, Wegovy, saw an impressive 91% surge—the fastest-growing revenue stream. Other revenue streams are also expanding rapidly. Their gross, operating, and net profit margins remain significantly higher than industry averages.

Full-Year 2024 Financial Performance

For the full fiscal year 2024, Novo Nordisk demonstrated strong financial growth:

• Revenue increased by 25%

• Gross margin rose by 0.1 percentage points to 84.7%

• Operating profit grew by 25%

• Net income climbed by 21%, with a similar increase in net income margin

The company continues to deliver double-digit growth, with GLP-1 drugs playing a crucial role. In comparison, Eli Lilly’s competing product is growing at a much slower rate.

Expanding Global Market Share

Novo Nordisk has nearly tripled its global patient reach over the past three years. Their GLP-1 market share has grown from 58% in 2021 to 63% today, while Eli Lilly’s has declined from 38% to 34%.

Exceptional Return on Invested Capital

The company boasts an extremely high Return on Invested Capital (ROIC)—currently at 56%, one of the highest seen on this channel. Despite a slight decline, this remains well above the 10% minimum typically sought after by investors.

Beating Market Expectations and Forecasts

Novo Nordisk’s recent earnings exceeded expectations, with Q4 net profit reaching $28.23 billion, surpassing the $26.09 billion market forecast. While Wegovy’s sales growth was slightly lower than market expectations, it still showed strong triple-digit growth.

Looking ahead, Novo Nordisk anticipates double-digit EPS growth over the next four quarters, with a 75% track record of beating earnings estimates (3 out of the last 4 quarters). Analysts project $4 EPS in 2025, placing its forward P/E at approximately 21—a reasonable valuation given its premium standing within the sector.

Growth Outpacing Industry and Historical Trends

Novo Nordisk’s revenue is expected to grow 21% year-over-year, well above both the sector average (mid-to-high single digits) and its own 5-year averages of 18% and 14%. EPS is growing even faster at 24%, compared to the sector's 11% and Novo Nordisk’s 5-year average of 14.3%. Despite these strong growth rates, the company is currently trading below its 5-year average valuation, making it an attractive candidate for deeper analysis.

Strong Sales, Profitability, and Cash Flow

Since 2021, Novo Nordisk has consistently achieved double-digit sales growth, culminating in a 25% increase in 2024. Profitability remains a key strength:

• Gross margin: 85% (sector average: 59%, 5-year average: 84%)

• Net income margin: 35% (sector median: negative -4%, 5-year average: 33.6%)

• Cash flow from operations: $17 billion, well above the 5-year average of $11 billion

• Sector median cash flow: -14 million (many competitors are losing cash)

Improving Margins and Long-Term Growth

Novo Nordisk continues to expand its margins, with its operating margin increasing from 43% a decade ago to 48% today. These trends highlight the company's ability to sustain growth while maintaining profitability, reinforcing its position as a strong long-term investment opportunity.

Consistent Free Cash Flow Generation

Novo Nordisk is a steady free cash flow machine, maintaining a 24% free cash flow margin in the most recent year.

Strong Balance Sheet and Low Debt

When evaluating net debt to EBITDA, a key indicator of financial stability, a ratio below 3 is ideal. Novo Nordisk consistently meets this benchmark, with a trailing twelve-month (TTM) ratio of 0.5, expected to decline further to 0.41. This demonstrates the company's strong financial position and ability to pay off all debt using available cash within a short period—something investors highly value.

Impressive Dividend Growth and Share Buybacks

Novo Nordisk has increased its dividend by 21% annually over the last 20 years. As a Dividend Aristocrat, the company has consistently raised dividends for over 25 years. In addition to dividends, Novo Nordisk actively repurchases shares, returning excess capital to shareholders. This commitment to capital allocation is evident in the declining share count over the past decade.

Expected Growth in 2025

Looking ahead, Novo Nordisk projects 16–24% revenue growth for 2025, along with another double-digit increase in operating profit.

Valuation and Price Target Analysis

Using a Discounted Cash Flow (DCF) model, the fair value of Novo Nordisk is estimated at $101, indicating a 26% upside from current levels. The valuation adjusts based on different discount rates:

• At 12% discount rate: Fair value is $87 (9% upside)

• At 16% discount rate: Fair value is $116 (45% upside)

Margin of Safety and Buy Zones

Applying a 10% margin of safety (MOS), a strong buy case emerges if the stock reaches $91. Investors looking for a 20% MOS should consider buying at $81, while those seeking a 25% or 30% MOS might wait for $76 or $71, respectively.

Wall Street’s Outlook Analysts remain bullish, with an average price target of $110—suggesting 38% upside over the next year.

Conclusion

Given the strong financials, undervaluation signals, and growth prospects, is Novo Nordisk a buy or sell for you? Let us know your thoughts!

Disclaimer: I want to make it clear that I am not a financial advisor, and nothing I say is intended to be a recommendation to buy or sell any financial instrument. Additionally, it's important to remember that there are no guarantees or certainties in trading or investing, and you should never invest money that you can't afford to lose.

@Daily_Discussion @TigerPM @TigerObserver @Tiger_comments @TigerClub